Insulin glargine (USAN/INN);
Insulin glargine (genetical recombination) (JP18);
Insulin glargine (genetical recombination) [Insulin glargin biosimilar 1] (JAN);
Insulin glargine (genetical recombination) [Insulin glargin biosimilar 2] (JAN);
Lantus (TN)

BASAGLAR (Eli Lilly and Company), INSULIN GLARGINE (A-S Medication Solutions), INSULIN GLARGINE (Biocon Biologics), INSULIN GLARGINE (Mylan Specialty L.P.), INSULIN GLARGINE (Sanofi-Aventis U.S. LLC), INSULIN GLARGINE (Winthrop U.S), INSULIN GLARGINE (Winthrop U.S.), INSULIN GLARGINE (sanofi-aventis U.S. LLC), INSULIN GLARGINE (sanofi-aventis U.S. LLC), INSULIN GLARGINE SOLOSTAR (A-S Medication Solutions), LANTUS (A-S Medication Solutions), LANTUS SOLOSTAR (A-S Medication Solutions), LANTUS SOLOSTAR (A-S Medication Solutions), REZVOGLAR (Eli Lilly and Company), REZVOGLAR KWIKPEN (A-S Medication Solutions), SEMGLEE (Biocon Biologics), SEMGLEE (Mylan Specialty L.P.), TOUJEO (A-S Medication Solutions), TOUJEO MAX (A-S Medication Solutions)

C267H404N72O78S6

6058.8184

6062.90

(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Gly
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr
Arg Arg
(Disulfide bridge: A6-A11, A7-B7, A20-B19)

Antidiabetic, Insulin receptor agonist

INSR (CD220) [HSA:3643] [KO:K04527]

CYP induction: CYP1A2 [HSA:1544]
DDI search